Kymera Therapeutics, Inc. (KYMR)
Health Care ยท Biological Products, (No Diagnostic Substances)
Kymera Therapeutics, Inc. (KYMR) is listed on Nasdaq, where its shares have traded since August 21, 2020. SentiSense covers Kymera Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances). Nello Mainolfi is its chief executive officer. The company reports 285 employees, and its corporate website is www.kymeratx.com.
About Kymera Therapeutics, Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
Latest reported results
Kymera Therapeutics Inc. reported revenue of $0.00 for Q3 FY2026, down 100.0% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 266 institutions reported holding KYMR, with 97.0 million shares worth $11.1 billion in aggregate. The largest reported holders were T. Rowe Price, FMR and Baker Bros. Advisors. Of the 5 largest reported holders, 3 added shares and 2 held their positions unchanged during the quarter.
More on KYMR
- KYMR sentiment: whether news and social coverage of Kymera Therapeutics, Inc. leans bullish or bearish, and the stories driving it.
- KYMR ownership: all 266 reporting institutions, plus insider and congressional trades.
- KYMR financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.
Frequently asked questions
What does Kymera Therapeutics, Inc. do?
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives.
What sector is KYMR in?
SentiSense classifies Kymera Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances).
Where does KYMR stock trade?
Kymera Therapeutics, Inc. (KYMR) is listed on Nasdaq, where its shares have traded since August 21, 2020.
Who is the CEO of Kymera Therapeutics, Inc.?
Nello Mainolfi is the chief executive officer of Kymera Therapeutics, Inc..